Register Interest

Biotome Pty Ltd

Biotome, founded in 2017 by Professor Samuel Lundin, Dr Alma Fulurija and Nobel Laureate Professor Barry Marshall, is developing next-generation serology tests (antibody-tests) based on precision immunology.

The COVID-19 pandemic has exposed the large performance issues of current antibody-test technologies. Our antibody tests are more informative and provide higher accuracy than current technology and will provide value in a range of disease diagnosis markets, including stomach cancer and SARS-CoV-2 infection.